These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17397004)

  • 21. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.
    Cummins JE; Doncel GF
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S84-91. PubMed ID: 19218890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.
    Fichorova RN; Bajpai M; Chandra N; Hsiu JG; Spangler M; Ratnam V; Doncel GF
    Biol Reprod; 2004 Sep; 71(3):761-9. PubMed ID: 15128598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract.
    Keller MJ; Herold BC
    Am J Reprod Immunol; 2006; 56(5-6):356-63. PubMed ID: 17076680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cervicovaginal evaluation in macaques used as a model for topical microbicide safety studies.
    Scorpio DG; Ruben DS; Liao Z; Hildreth JE; Fletcher CA
    J Med Primatol; 2008 Feb; 37 Suppl 1():65-73. PubMed ID: 18269532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
    Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
    Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
    Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R
    Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical assessments of vaginal microbicide candidate safety and efficacy.
    Fernández-Romero JA; Teleshova N; Zydowsky TM; Robbiani M
    Adv Drug Deliv Rev; 2015 Sep; 92():27-38. PubMed ID: 25543007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal toxicity studies of a gel formulation of native pokeweed antiviral protein.
    D'Cruz OJ; Waurzyniak B; Uckun FM
    Toxicol Pathol; 2004; 32(2):212-21. PubMed ID: 15200159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First real success for anti-HIV gel: a new start for HIV microbicides?
    Ariën KK; Vanham G
    Future Microbiol; 2010 Nov; 5(11):1621-3. PubMed ID: 21133683
    [No Abstract]   [Full Text] [Related]  

  • 31. A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation.
    Fichorova RN; Mendonca K; Yamamoto HS; Murray R; Chandra N; Doncel GF
    Toxicol Appl Pharmacol; 2015 Jun; 285(3):198-206. PubMed ID: 25818602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
    Lindqvist M; Persson J; Thörn K; Harandi AM
    J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interrupting herpes simplex virus type 2 transmission: the role of condoms and microbicides.
    Langenberg A
    Herpes; 2004 Aug; 11 Suppl 3():147A-154A. PubMed ID: 15319084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model.
    Patton DL; Cosgrove Sweeney YT; Paul KJ
    Sex Transm Dis; 2008 Oct; 35(10):889-97. PubMed ID: 18607310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure.
    Mauck CK; Lai JJ; Weiner DH; Chandra N; Fichorova RN; Dezzutti CS; Hillier SL; Archer DF; Creinin MD; Schwartz JL; Callahan MM; Doncel GF
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1475-86. PubMed ID: 23885658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New candidate biomarkers in the female genital tract to evaluate microbicide toxicity.
    Fields S; Song B; Rasoul B; Fong J; Works MG; Shew K; Yiu Y; Mirsalis J; D'Andrea A
    PLoS One; 2014; 9(10):e110980. PubMed ID: 25333937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colposcopy: still useful in microbicide safety trials?
    Mauck CK; Weiner DH; Lai JJ; Schwartz JL
    Sex Transm Dis; 2012 Jun; 39(6):465-9. PubMed ID: 22592833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
    O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
    Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tests of vaginal microbicides in the mouse genital herpes model.
    Zeitlin L; Whaley KJ; Hegarty TA; Moench TR; Cone RA
    Contraception; 1997 Nov; 56(5):329-35. PubMed ID: 9437563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.